Xeris Biopharma officer exercises 48,898 stock options

Xeris Biopharma Holdings, Inc. officer Kevin McCulloch exercised stock options to acquire a total of 48,898 shares of common stock on March 12, 2026, at exercise prices of $4.09 and $3.94 per share.

Rhea-AI Filing Summary

Xeris Biopharma Holdings, Inc. officer Kevin McCulloch exercised stock options to acquire a total of 48,898 shares of common stock on March 12, 2026, at exercise prices of $4.09 and $3.94 per share. These options were granted under the company’s 2018 Stock Option/Stock Issuance Plan and had fully vested based on prior service conditions. Following the transactions, he holds 1,777,725 common shares directly and 25,000 shares indirectly through his spouse. The filing notes he disclaims beneficial ownership of some reported securities beyond his pecuniary interest.

Insider Trade Summary

48,898 shares exercised/converted

Exercise 5 txns

Insider McCulloch Kevin

Role See Remarks

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	48,894	$4.09	$200K
Exercise	Stock Option (Right to Buy)	4	$3.94	$15.76
Exercise	Common Stock	48,894	$4.09	$200K
Exercise	Common Stock	4	$3.94	$15.76
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 123,769 contracts (Direct); Common Stock — 1,777,725 shares (Direct); Common Stock — 25,000 shares (Indirect, By Spouse)

Footnotes (3)

1. F1. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
2. F2. The reporting person received the stock options on December 10, 2020 pursuant to an award under the Company's 2018 Stock Option/Stock Issuance Plan (the "2018 Plan"). 50% of the options vested on the first anniversary of the vesting commencement date, and the remaining 50% of options vested on the second anniversary of the vesting commencement date, in each case subject to continued employment through such vesting date.
3. F3. The reporting person received the stock options on August 26, 2020 pursuant to an award under the 2018 Plan. 50% of the options vested on the first anniversary of the vesting commencement date, 25% of the options vested on the 18-month anniversary of the vesting commencement date, and the remaining 25% of options vested on the two-year anniversary of the vesting commencement date, in each case subject to continued employment through such vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Xeris Biopharma (XERS) report for Kevin McCulloch?

Kevin McCulloch exercised stock options to acquire 48,898 Xeris Biopharma common shares. The options were exercised on March 12, 2026 at exercise prices of $4.09 and $3.94 per share, converting previously granted options into directly held common stock.

How many Xeris Biopharma shares does Kevin McCulloch hold after this Form 4?

After the reported transactions, Kevin McCulloch holds 1,777,725 Xeris Biopharma common shares directly. The filing also shows an additional 25,000 common shares held indirectly through his spouse, giving investors a clearer picture of his total reported equity exposure.

Were any Xeris Biopharma shares sold in Kevin McCulloch’s latest Form 4 filing?

The Form 4 shows option exercises that increased McCulloch’s common share holdings, with no reported open-market sales. All coded transactions use “M” for derivative exercise or conversion, indicating conversion of stock options into common shares rather than share disposals.

What were the exercise prices of Kevin McCulloch’s Xeris Biopharma stock options?

McCulloch exercised options at $4.09 and $3.94 per share. These stock options, granted under Xeris Biopharma’s 2018 Stock Option/Stock Issuance Plan, had fully vested according to their service-based vesting schedules before being exercised into common stock.

How were Kevin McCulloch’s exercised Xeris Biopharma options originally granted and vested?

The options were granted under the 2018 Stock Option/Stock Issuance Plan with multi-year vesting. Footnotes state portions vested on the first, 18‑month, and second anniversaries of the vesting commencement date, all subject to continued employment through each vesting milestone.

What does the beneficial ownership disclaimer mean in the Xeris Biopharma Form 4?

The Form 4 states McCulloch disclaims beneficial ownership of some reported securities beyond his pecuniary interest. This standard language clarifies that inclusion of certain shares, such as those held indirectly, is not an admission of full beneficial ownership for regulatory purposes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/16/2026 - 06:11 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McCulloch Kevin

(Last) (First) (Middle)

C/O XERIS BIOPHARMA HOLDINGS, INC.

1375 WEST FULTON STREET, SUITE 1300

(Street)

CHICAGO IL 60607

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Xeris Biopharma Holdings, Inc. [ XERS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
03/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/12/2026		M		48,894	A	$4.09	1,777,721	D
Common Stock	03/12/2026		M		4	A	$3.94	1,777,725	D
Common Stock								25,000(1)	I	By Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$4.09	03/12/2026		M			48,894	(2)	12/10/2027	Common Stock	48,894	$4.09	43,773	D
Stock Option (Right to Buy)	$3.94	03/12/2026		M			4	(3)	08/26/2030	Common Stock	4	$3.94	79,996	D

Explanation of Responses:

1. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

2. The reporting person received the stock options on December 10, 2020 pursuant to an award under the Company's 2018 Stock Option/Stock Issuance Plan (the "2018 Plan"). 50% of the options vested on the first anniversary of the vesting commencement date, and the remaining 50% of options vested on the second anniversary of the vesting commencement date, in each case subject to continued employment through such vesting date.

3. The reporting person received the stock options on August 26, 2020 pursuant to an award under the 2018 Plan. 50% of the options vested on the first anniversary of the vesting commencement date, 25% of the options vested on the 18-month anniversary of the vesting commencement date, and the remaining 25% of options vested on the two-year anniversary of the vesting commencement date, in each case subject to continued employment through such vesting date.

Remarks:

President and Chief Operating Officer

	/s/ Beth Hecht, Attorney-in-Fact	03/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.